E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Obesity Related Male Hypogonadism |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029883 |
E.1.2 | Term | Obesity |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10021011 |
E.1.2 | Term | Hypogonadism male |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the research project is to determine the effect of twelve weeks’ treatment with an aromatase inhibitor (Femara®, 2.5mg weekly) on the change in the serum concentration of the pro-inflammatory cytokine, C Reactive Protein, as measured by the Roche® Cobas immuno-turbidimetric test and compare it to that of twelve weeks’ treatment with a depot intramuscular formulation of testosterone undecanoate (Nebido®, 1g every 6 weeks) and to that of six weeks of no treatment. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the research project are to determine the effect of twelve weeks’ treatment with Femara® compared to Nebido® and compared to no treatment on: 1. The change in the serum concentration of other pro-inflammatory cytokines: IL-6, TNFα, IL1β, IFNγ; 2. The change in the time taken to walk 500m at a moderately intense pace; 3. The change in erectile function, as measured by the International Index of Erectile Function (IIEF); 4. The change in modifiable cardiovascular disease risk factors including blood pressure, glycosylated haemoglobin, insulin resistance, lipid fractions and weight as measured by standard, hospital standard, clinical methods; 5. The change in quality of life. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Men who satisfy all of the following may be included in the study: 1. Age between 18 and 65 years inclusive 2. Body mass index (BMI) greater than 30kg/m2 3. Serum total testosterone concentrations less than 8.0nmol/L on two consecutive occasions. The blood that will be used for measurement of the testosterone concentrations will be taken from research participants after a 12 hour fast and between the hours of 0800 to 1100. 4. Willingness to voluntarily sign a statement of informed consent to participate in the study. |
|
E.4 | Principal exclusion criteria |
Men with any of the following conditions will be excluded from the study: 1. Use of systemic glucocorticoid, sex hormone or anticoagulant therapy, or a medication known to effect sex hormone bioactivity during the 6 months prior to study entry (i.e. screening visit) 2. Known hypersensitivity to the active substances or any of the excipients of Femara® or Nebido® 3. Hypothalamic pituitary disease 4. Untreated obstructive sleep apnoea syndrome 5. Haemophilia 6. Psychotic mental illness 7. Inability to understand the participant information or to give informed consent 8. History of cancer 9. History of prostatic intra-epithelial neoplasia (PIN) 10. Severe lower urinary tract symptoms (International Prostate Symptom Score >19) 11. Erythrocytosis (Haematocrit > 0.5, or Haemoglobin > 17g/dl) 12. Prostate specific antigen (PSA) level >3ng/ml 13. Moderate to severe chronic kidney disease (eGFR <30ml/min/1.73m2) 14. Severe liver disease (serum Alanine Transferase level >150IU/L) 15. Significant cardiomyopathy (Left ventricular ejection fraction <30%) 16. Greater than 2 seizures during the 12 months prior to study entry 17. Requiring fertility treatment 18. Any clinically significant chronic disease that might, in the opinion of the investigator, interfere with the evaluations or preclude completion of the trial (e.g. severe chronic lung disease, terminal illness) 19. Previous randomisation into this study 20. Concurrent participation in another clinical trial 21. Participation in another clinical trial during the twelve weeks prior to study entry (i.e. screening visit) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the change in the concentration of serum C Reactive Protein after twelve weeks as measured by the Roche® Cobas immuno-turbidimetric test on the Roche® platform. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The trial will end when the last research participant completes his last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |